Published in Cancer Weekly, December 12th, 2000
The Commission decision follows a positive opinion adopted on September 13, 2000, by the Committee on Orphan Medicinal Products (COMP) of the European Agency for the Evaluation of Medicinal Products (EMEA).
"We anticipate that Mylotarg will become an important treatment option for European patients age 60 and over with CD33-positive relapsed acute myeloid leukemia (AML)," said L. Patrick Gage, PhD, Wyeth-Ayerst Research. "Its mechanism of action focuses on using antibody-antigen...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.